New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 9, 2013
10:12 EDTRDYDr. Reddy's Labs relocating N.A. headquarters to Princeton, NJ
Dr. Reddy’s Laboratories announced plans to relocate its North America Headquarters and establish a R&D Center in Princeton, New Jersey. Dr. Reddy’s, represented by Jones Lang LaSalle, has entered into two lease agreements for a 75,500 square foot office facility and a 31,000 square foot office/lab. Dr. Reddy’s anticipates relocation to the office facility at 107 College Road East by the end of the summer of 2013 after the renovations to the facility are completed. The lab facility is also expected to be completed by late summer to early fall of 2013 and will employ 35 scientists, chemists and support personal.
News For RDY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 8, 2015
12:17 EDTRDYOn The Fly: Midday Wrap
Subscribe for More Information
05:10 EDTRDYDr. Reddy's Labs files three NDAs with FDA
Dr. Reddy's Laboratories and its subsidiary, Promius Pharma, announced the filing of three 505(b)(2) New Drug Applications, or NDAs, with the FDA. The three NDAs - DFD-01, DFD-09, and DFN-11, are in support of Dr. Reddy’s Proprietary Products group, focused on developing and commercializing therapies in dermatology and neurology. DFD-01 and DFD-09 are the first dermatology applications submitted to the NDA that have been fully developed leveraging in-house capabilities. DFD-01 is a corticosteroid delivered in a novel non-irritating spray platform, intended for the treatment of patients suffering from psoriasis. DFD-09 is a modified release oral tetracycline intended for the treatment of rosacea. DFN-11 is the first development program filed in support of a newly created vertical, focused on the U.S. neurology market. DFN-11 is a drug-device combination product intended to treat acute migraine episodes in certain patient populations who are inadequately managed with existing treatment regimens.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use